WELCOME BACK: Drugmakers’ top lobbying group is welcoming lawmakers back to town this week with a seven-figure ad blitz, ramping up pressure on Congress to enact a crackdown on pharmaceutical ...

Today, Congresswoman Nikki Budzinski (IL-13) hosted a roundtable with independent pharmacists, pharmacy students and faculty ...

For example, the big-three PBMs are the dominant middlemen in drug transactions, and they’re each part of a company that also owns a top-10 insurer. So they could try to get better deals for their ...

It remains to be seen how well President Joe Biden’s Inflation Reduction Act will actually work in lowering prescription drug ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

The election could have major impacts on drug prices, Medicaid, the Affordable Care Act, public health agencies, abortion, ...

A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

Congresswoman Nikki Budzinski (IL-13) will host a roundtable discussion with independent pharmacists on Saturday, November 2, ...

Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...

PBMs represent insurers in drug transactions, and they decide which medicines will be covered. And, because just three PBMs control access to about 80% of insured patients, they have enormous ...